What the studies show
Among participants with baseline liver fat above 10%: −66% (4 mg) and −80% (6 mg) versus −5% in GLORY-1; −72% versus +5% in GLORY-2.
Human trials exist and mostly agree, but there are too few of them, they are too small, or one big one is still reading out. Expect the grade to move.
- 1Ji L, et al. Once-weekly mazdutide in Chinese adults with obesity or overweight (GLORY-1).N Engl J Med, 2025; DOI 10.1056/NEJMoa2411528610 adults, 48 weeks.
- 2Gao L, et al. Treatment with 9-mg mazdutide for weight reduction in Chinese adults with obesity: the GLORY-2 randomized clinical trial.JAMA, 2026;336:377–388461 adults, 60 weeks on 9 mg; −16.65% versus −1.50%.
In context
Mazdutide is a once-weekly GLP-1/glucagon dual agonist developed by Innovent with Lilly. In the 610-person GLORY-1 trial, published in the New England Journal of Medicine in May 2025, it produced 14.8% weight loss at 48 weeks on 6 mg against 0.5% on placebo; a 9 mg dose reached 16.7% at 60 weeks in the peer-reviewed GLORY-2 trial. China's regulator approved it for chronic weight management on 27 June 2025 and later for type 2 diabetes. It is not approved in the US, EU or UK.
Mazdutide is approved in china only. Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Mazdutide proven to help with liver fat?
What studies are behind the grade?
Is Mazdutide approved for this?
Other outcomes for Mazdutide
- ABody weight2 phase 3 RCTs
- ABlood glucose (HbA1c)DREAMS phase 3 programme
- AGI side effectsadversePhase 3
Written and maintained by LYO Research — how pages are written and checked. Reviewed 3 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →